Prospective Head and Neck Cancer Research: a Four-Decade Bibliometric Perspective
About this course
- Released: 05/27/2013
- Expires: 05/27/2015
- Time to Complete: 1.00 hour
- Medium: Internet Online
The CME quiz and evaluation must be completed by the expiration date above, in order to receive the credit or a participation certificate. Click here to learn more about our review process.
- Read the following information before beginning the educational activity and click the "Take this course" link at the bottom of the page
- Study the educational activity
- Complete the CME quiz and evaluation
- After successful completion of the CME quiz and evaluation, you will receive the credit or participation certificate
Physicians who wish to advance their current knowledge of head and neck cancers.
- Discuss the prevalence of pharmacotherapy, radiotherapy, and surgery in prospective head and neck cancer therapeutic research.
- Describe trends in the gender, country, and continent of origin of first and corresponding authors of prospective head and neck cancer therapeutic research.
Accreditation and Credit Designation
The Society for Translational Oncology is accredited by the ACCME to provide continuing medical education for physicians.
The Society for Translational Oncology designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
In compliance with the ACCME Standards of Commercial Support, it is the policy of the Society for Translational Oncology to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities and to include information free of commercial bias and based on the best evidence available. All individuals in a position to influence the content of this activity have disclosed relevant financial interests or relationships of their own, their spouse/partner, or their worksite, with manufacturers or providers of commercial products, services, technology, or programs; and disclosed relationships with current non-governmental supporters of the activity.
All information is submitted and reviewed and found to be scientifically rigorous, based on the best available evidence, fair and balanced, and free of commercial bias. All the recommendations involving clinical medicine in this CME activity are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection and analysis.
Any potential conflicts of interests are resolved via The Oncologist's anonymous peer review process: http://authors.theoncologist.com/conflicts-of-interest. All manuscripts are reviewed by the Editorial Board with ad hoc assistance from two or more external experts in the field. All final publication decisions are made by the Editorial Board. The acceptance of a manuscript is based on its originality and importance to the field as assessed by the Editors.
Section Editor Disclosures
Independent Peer Review Disclosures
Reviewer "A" discloses honoraria received from Pfizer and Boehringer-Ingelheim and research funding received from Pfizer.
CME Activity Directors Disclosures
Frank M. Balis, M.D., CME Program Co-Editor, Director of Oncology Clinical Research, The Children's Hospital of Philadelphia, has disclosed no financial relationships relevant to the content of these articles.
Michael J. Haut, M.D., CME Program Co-Editor, Clinical Professor of Medicine, Pennsylvania Hospital, University of Pennsylvania, Philadelphia, Pennsylvania, has disclosed no financial relationships relevant to the content of these articles.
Jayne S. Gurtler, M.D., F.A.C.P., CME Program Associate Editor, East Jefferson General Hospital, Metairie, Louisiana, discloses research funding from sanofi-aventis, GlaxoSmithKline, and Eli Lilly.
Staff Planners Disclosures
No financial relationships relevant to the content of this article have been disclosed by the staff planners.
The Oncologist CME Online supports the following browsers: Current production versions of Safari, Firefox, Internet Explorer and Chrome.
The Editors are grateful for an educational grant from Lilly USA, LLC in partial support of our Journal CME program.
The Oncologist CME Online
318 Blackwell Street, Suite 270
Durham, North Carolina 27701
Phone: (919) 433-0489
Fax: (919) 680-4411